Extraintestinal Manifestations and Intestinal Complications in Patients with Crohn's Disease: Associations with Some Clinico-Laboratory Findings, Immunological Markers and Therapy

1. Friedman Set Blumberg S. Chapter 295 Inflammatory Bowel Disease. In: Harrison’s Principles of Internal Medicine, 18 edition, Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J, USA, 2012.Search in Google Scholar

2. Ha F et Khalil H. Crohn’s disease: a clinical update. Ther Adv Gastroenterol, 2015, 8(6), 352-359.10.1177/1756283X15592585Search in Google Scholar

3. Levine JS et Burakoff B. Extraintestinal Manifestations of Inflammatory Bowel Disease. Gastroenterology & Hepatology, 2011, 7(4), 235-241.Search in Google Scholar

4. Bernstein CN, Fried M, Krabshuis JH et al. World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of IBD in 2010. Inflammatory Bowel Diseases, 2010, 16(1), 112-114.10.1002/ibd.21048Open DOISearch in Google Scholar

5. Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol, 2006, 12(30), 4819-31.10.3748/wjg.12.4819Search in Google Scholar

6. Vavricka SR, Schoepfer A, Scharl M et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis, 2015, 21, 1982-1992.10.1097/MIB.0000000000000392Search in Google Scholar

7. Spekhorst LM, Imhann F, Festen EA on behalf of the Parelsnoer Institute (PSI) and the Dutch Initiative on Crohn and Colitis (ICC), et al. Cohort profile: design and first results of the Dutch IBD Biobank: a prospective, nationwide biobank of patients with inflammatory bowel disease. BMJ Open, 2017, 7, e016695.10.1136/bmjopen-2017-016695Search in Google Scholar

8. Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 2006, 55, 749-753.10.1136/gut.2005.082909Search in Google Scholar

9. Freeman HJ. Natural history and long-term clinical course of Crohn’s disease. World J Gastroenterol, 2014, 20(1), 31-36.10.3748/wjg.v20.i1.31Open DOISearch in Google Scholar

10. Hellers G. Crohn’s disease in Stockholm county 1955-1974. A study of epidemiology, results of surgical treatment and longterm prognosis. Acta Chir Scand Suppl, 1979, 490, 1-84.Search in Google Scholar

11. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis, 2002, 8(4), 244-50.10.1097/00054725-200207000-00002Open DOISearch in Google Scholar

12. Fedorak RN. Is it time to re-classify Crohn’s disease? Best Pract Res Clin Gastroenterol, 2004, 18 Suppl, 99-106.10.1016/j.bpg.2004.06.018Open DOISearch in Google Scholar

13. Herfarth HH, Long MD, Kappelman MD. Immunosuppression for management of Crohn’s disease. The Lancet, 2016, 387(10020), 747-748.10.1016/S0140-6736(16)00327-5Search in Google Scholar

14. Khanna, R, Bressler, B, Levesque, BG et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet, 2015, 386, 1825-1834.10.1016/S0140-6736(15)00068-9Search in Google Scholar

15. D’Haens, G, Baert, F, van Assche, G et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet, 2008, 371, 660-667.10.1016/S0140-6736(08)60304-9Search in Google Scholar

16. Colombel, JF, Sandborn, WJ, Reinisch, W et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med, 2010, 362, 1383-1395.10.1056/NEJMoa090449220393175Search in Google Scholar

17. Lakatos PL, Lakatos L, Kiss LS et al. Treatment of extraintestinal manifestations in inflammatory bowel disease. Digestion, 2012, 86 (Suppl 1), 28-35.10.1159/00034195023051724Search in Google Scholar

18. Iskandar HN, Ciorba MA. Biomarkers in inflammatory bowel disease: current practices and recent advances. Transl Res, 2012, 159(4), 313-25.10.1016/j.trsl.2012.01.001330811622424434Search in Google Scholar

19. Benor S, Russell GH, Silver M et al. Shortcomings of the inflammatory bowel disease Serology 7 panel. Pediatrics, 2010, 125(6), 1230-6.10.1542/peds.2009-193620439597Search in Google Scholar

20. Velikova TV. Investigations of immunological parameters for intestinal inflammation in order to establish new markers for diagnosis and follow-up of inflammatory bowel disease. Dissertation 2014. Medical university of Sofia.Search in Google Scholar

21. Lewis JD. The Utility of Biomarkers in the Diagnosis and Therapy of Inflammatory Bowel Disease. Gastroenterology, 2011, 140(6), 1817-1826.10.1053/j.gastro.2010.11.058374929821530748Search in Google Scholar